洛赛克联合硫糖铝、阿莫西林治疗消化性溃疡并幽门螺杆菌感染的疗效观察.docVIP

精品论文 参考文献 洛赛克联合硫糖铝、阿莫西林治疗消化性溃疡并幽门螺杆菌感染的疗效观察 尚文法(山东省蒙阴县中医医院内一科 山东蒙阴 276200) 【中图分类号】R573.6【文献标识码】A【文章编号】1672-5085（2012）18-0134-02 【摘要】目的 通过比较2种治疗消化性溃疡的三联疗法的治愈率和幽门螺杆菌的根除率，探讨较为理想的消化性溃疡治疗和幽门螺杆菌的根除方案。方法 选取60例感染了幽门螺杆菌的消化性溃疡患者，采用随机数字表法分为A、B2组，每组30例，分别接受洛赛克、硫糖铝、阿莫西林2周三联疗法和硫糖铝、甲硝唑、阿莫西林2周三联疗法治疗，治疗结束后4周应用胃镜和活检染色对溃疡治愈率和幽门螺杆菌根除率进行分析。结果 A、B2组溃疡治愈率差异无统计学意义（93.3％vs83.3％,pgt;0.05）,但A组患者幽门螺杆菌的根除率要高于B组（96.6％vs80％,plt;0.05）。结论 洛赛克、硫糖铝和阿莫西林2周三联疗法是一种更为理想的消化性溃疡治疗方案。 【关键词】三联疗法 消化性溃疡 疗效 幽门螺杆菌 Clinical Observation of Losec Joint Sucralfate、Amoxicillion in the Treatment of Peptic Ulcer and Helicobacter Pylori Infecion 【Abstract】　Objective To explore a more ideal program of treatment of peptic ulcer and Helicobacter pylori by comparing the cure rate and the Helicobacter pylori eradication rate of two kinds of triple therapy for peptic ulcer.Methods Sixty patients with peptic ulcer infected with Helicobacter pylori were divided into group A and group B by random table method ,and were treated with losec ,sucralfate and amoxicillin for two weeks for group A(n=30)or suralfate ,metronidazole and amoxicillin for two weeks for group B(n=30),respectively.The endoscopy and biospy staining were used to analysis the cure rate and the Helicobacter pylori eradication rate at the 4th week after the end of the treatment.Results There was no difference between group A and B in reptic ulcer rate (93.3％％vs83.3％,pgt;0.05),but the Helicobacter pylori eradication rate of group A was higher than that of group B（96.6％vs80％，plt;0.05,）.Conclusion losec,sucralfate and amoxicillin two-week triple therapy is a more ideal treatment program for peptic ulcer. 【Key words】　triple therapy peptic ulcer curative effect Helicobacter pylori 消化性溃疡（胃、十二指肠溃疡）是一种常见病，据估计，约10％的人患过此病[1]。病理学认为消化性溃疡是攻击因子（胃酸、胃蛋白酶的分泌、幽门螺杆菌感染）与防御或细胞保护因子（黏液分泌、重碳酸盐分泌、前列腺素的产生）失衡所致。而幽门螺杆菌是其主要致病因子，消化性溃疡患者感染幽门螺杆菌的比例非常高。研究表明，根除幽门螺杆菌后溃疡复发率和并发症可明显降低[2]，选择根除幽门螺杆菌药物已成为提高消化性溃疡愈合质量，防止复发的关键，所以对幽门螺杆菌阳性消化性溃疡，不仅要治愈溃疡，还应根除幽门螺杆菌，才能减少溃疡复发。质子泵受体阻滞剂洛赛克对胃酸有很强的抑制作